Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(17):1235; doi:10.1093/jnci/dji323
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hayasaka, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hayasaka, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

MEMO TO THE MEDIA

Press Release

Letrozole Following Tamoxifen May Benefit Women With Breast Cancer

Elana Hayasaka

jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute

The first 10% of the full text of this article appears below.

Switching to the drug letrozole following 5 years of treatment with tamoxifen reduces the risk of hormone-dependent breast cancer recurrence, but not overall survival, among postmenopausal women, according to a new study in the September 7 issue of the Journal of the National Cancer Institute.

The standard treatment for women with estrogen receptor-positive breast cancer is 5 years of tamoxifen. Extending . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?